RESTYLANE® EYELIGHT™

Key Uses of Restylane EyeLight with Lidocaine

• Under-eye hollows: Fills in hollows to provide a smoother appearance.
• Dark circles: Reduces the appearance of dark circles by adding volume.
• Fine lines: Smooths fine lines around the eyes.
• Volume loss: Addresses volume loss in the tear trough area.

Manufacturing Information for Restylane EyeLight with Lidocaine

Restylane EyeLight with Lidocaine is manufactured by Galderma, a global leader in dermatology and aesthetic solutions based in Switzerland. Galderma is renowned for its extensive range of Restylane products, including Restylane Lyft, Restylane 1ml with Lidocaine, and Restylane Skinbooster Vital. Aesthetic clinics and practices can buy Restylane dermal fillers online at Kinami Health shop at wholesale prices and discounts with fast delivery options.

Expected Benefits and Results of the Treatment

• Restores volume and reduces dark circles.
• Quick procedure with minimal downtime.
• Results can last up to 12 months.
• Lidocaine ensures a more comfortable treatment experience without pain.
• Suitable for various under-eye concerns.
• Hyaluronic acid improves skin hydration.
• Noticeable improvements immediately after treatment.

Restylane EyeLight with Lidocaine Key Ingredients and Device Features

• Lidocaine (3 mg/ml): Provides pain relief during the procedure.
• Hyaluronic acid (20 mg/ml): Restores volume and hydrates the skin.
• Phosphate buffered saline pH 7: Ensures stability and safety.
• Smooth gel consistency: Allows precise application.
• Biodegradable: Naturally breaks down in the body over time.
• Non-animal origin: Reduces the risk of allergic reactions.
• Stabilized formula: Ensures longer-lasting results.

Included Items or Accessories

Restylane EyeLight with Lidocaine pack includes:

• 1 x pre-filled syringe (0.5ml) of Restylane EyeLight with Lidocaine
• 1 x sterile 29G1/2” needle
• Product leaflet
• Traceability labels

Administration Method for Restylane EyeLight with Lidocaine

Administering Restylane EyeLight with Lidocaine should go as follows to ensure optimal results and patient safety:

• Pre-procedure: Conduct a thorough patient consultation to understand their needs and medical history. Clean the treatment area thoroughly. Apply topical anesthesia if necessary.
• During the procedure: Use the pre-filled syringe with the provided needle to inject the filler slowly and evenly. Monitor patient comfort throughout the procedure.
• Post-procedure: Provide the patient with detailed post-treatment care instructions. Advise on potential side effects and how to manage them. Schedule a follow-up appointment to assess the results and plan future treatments if necessary.

Guidelines for Proper Aftercare

Post-treatment care after procedure with Restylane EyeLight filler includes:

• Do not exercise and avoid moderate to high physical activities for 24 hours.
• Refrain from touching or massaging the treated area.
• Use cold compresses to reduce swelling.
• Avoid excessive sun exposure and tanning beds.
• Wear sunscreen and glasses to protect your under-eye area from UV radiation.

Duration of Restylane EyeLight with Lidocaine Effects

Restylane EyeLight offers results that typically last up to 12 months. However, to maintain those results, patients should have a follow-up treatment every 9-12 months.

Potential Risks and Side Effects

Restylane EyeLight with Lidocaine may cause side effects, though they are generally mild and temporary:

• Common: Lumps, bumps, redness, swelling, bruising, tenderness, pain.
• Rare: Infection, allergic reactions, nodules, discoloration, itching.
  If rare side effects persist and become severe, patients should seek medical attention immediately.

Contraindications for the Treatment

Restylane EyeLight with Lidocaine is not suitable for everyone and contraindications for the treatment include:

• Individuals with severe allergies.
• Patients with bleeding disorders.
• Pregnant or breastfeeding women.
• Those with a history of anaphylaxis.
• People with active skin infections in the treatment area.
• Patients with autoimmune diseases.
• Individuals with untreated epilepsy.
• Patients who are underaged.